HUCOG 10000IU is widely known as Novarel, Ovidrel, Pregnyl, Human chorionic gonadotropin, hCG
HUCOG 10000IU
(hCG): Bharat Serums, hCG, Human Chorionic Gonadotropin, hCG, Human Chorionic Gonadotropin, Novarel , HUCOG
Comes with 3 x 10000 IU
All of these are different brands of the same active substance – hCG
Highly Purified Chorionic Gonadotrophin Injection HUCOG®
10000 HP
For Subcutaneous / Intramuscular Injection only
Composition :
Each ml contains :
Chorionic Gonadotrophin highly purified I.H
2000 I.U. / 5000 I.U. / 10000 I.U.
Water for Injection I.P
q.s.
Excipients & Stabilizers :
Disodium Hydrogen Phosphate Dihydrate I.P., Benzyl Alcohol I.P., Sucrose I.P., Poloxamer
188
U.S.P./NF, Methionine B.P., Phosphoric acid I.P.
One IU of Chorionic Gonadotrophin is defined as the activity contained in 1.279 mg of the 2nd International
Standard Preparation.
Properties :
Chorionic Gonadotrophin (HCG) is a hormonal substance obtained from urine of pregnant women. Its
action is predominantly luteinizing.
Indications :
Anovulatory infertility :
In the female, HUCOG HP is used in the treatment of anovulatory infertility. where its administration would
form part of recognized treatment regimen involving prior stimulation of follicular maturation and
endometrial proliferation e.q. with Menotropin Injection (HUMOG HP).
Hypogonadotrophin hypogonadism and cryptorchidism :
In the male, HUCOG HP stimulates the interstitial cells of the testes and consequently the secretion of
androgens and the development of secondary sexual characteristics. With concomitant Menotropin
Injection therapy, HUCOG HP stimulates the induction and maintenance of spermatogenesis.
Dosage and Administration :
HUCOG HP is given by subcutaneous / intramuscular injection only.
Anovulatory infertility :
HUCOG HP 10000 I.U. is administered in mid-cycle, following treatment with Menotropin Inj. (HUMOG HP)
according to a recognised scheme. Details of Menotropin Inj. (HUMOG HP) dosage and monitoring are
available on request.
Hypogonadotrophic hypogonadism :
HUCOG HP 2000 I.U. twice weekly concomitant with Menotropin Inj. (HUMOG HP) (1 vial three times a
week) if necessary for a minimum period of four months.
Cryptorchidism :
Equivalent to 1000 I.U. of HUCOG HP on alternate days for several weeks.
Contra-Indication and Warnings :
Stimulation of ovulation with HUCOG HP may lead to superovulation and the hyperstimulation syndrome.
Oestrogen assays will detect the excessive response so that HUCOG HP (HCG) may be withheld in that
particular treatment cycle. In the male, high dosages of HUCOG HP may lead to oedema and in such
cases dosages should be considerably reduced.
If signs of sexual precocity are observed a reduced dosage regimen should be instituted.
Side Effects :
Headache, irritability, restlessness, depression, fatigue, edema, gynecomastia, sexual precocity, pain at
the site of injection.
Adverse Events :
The adverse reactions for use in infertility are: (1) Ovarian hyperstimulation (OHSS), a syndrome of
sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion, (2) Rupture of ovarian
cysts with resultant hemoperitoneum, (3) Multiple births, and (4) Arterial thrombo-embolism.
PRECAUTION :
HCG should be used in conjunction with human menopausal gonadotropins only by physicians
experienced with infertility problems who are familiar with the criteria for patient selection,
contraindications, warnings, precautions, and adverse reactions described in the package insert for
menotropins.
Interaction with other medicinal products and other forms of interaction :
Concomitant use of HuCoG Injection with other agents used to stimulate ovulation
(e.g. HMG,
clomiphene citrate) may potentiate the follicular response. (See Warnings Precaution & Overdosage.)
Overdose :
The effects of an overdose of HuCoG Injection are unknown, nevertheless one could expect ovarian
hyperstimulation syndrome (OHSS) to occur, which is further described as below:
Ovarian Hyperstimulation Syndrome (OHSS) : (See Warnings) :
OHSS is a medical event distinct from uncomplicated ovarian enlargement. OHSS is a syndrome that can
manifest itself with increasing degrees of severity. It comprises marked ovarian enlargement, high serum
sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the
peritoneal, pleural and, rarely, in the pericardial cavities.
The following symptomatology may be observed in severe cases of OHSS : abdominal pain,
abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal
symptoms including nausea, vomiting and diarrhoea.
Adherence to recommended HuCoG Injection dosage, regimen of administration and careful monitoring
of therapy will minimize the incidence of ovarian hyper stimulation and multiple gestations. In ART,
aspiration of all follicles prior to ovulation may reduce the occurrence of hyper stimulation. OHSS may be
more severe and more protracted if pregnancy occurs. Most often, OHSS occurs after hormonal treatment
has been discontinued and reaches its maximum at about seven to ten days following treatment. Usually,
OHSS resolves spontaneously with the onset of menses. If severe OHSS occurs, gonadotrophin treatment
should be stopped if still ongoing, the patient hospitalized and specific therapy for OHSS started. This
syndrome occurs with higher incidence in patients with polycystic ovarian disease.
Ovarian response should be carefully monitored to minimize the risk of overstimulation. If the ovaries are
abnormally enlarged on last day of gonadotrophin therapy, HCG should not to be administered in this
course therapy. This reduces development of OHSS (Ovarian Hyperstimulation Syndrome). Use of
ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels can further
minimize the risk of overstimulation.
Storage :
Vials of HUCOG HP should be stored between 20C – 80C. Do not freeze. Protect from light. Any unused
portion should be discarded.
Presentation :
HUCOG HP is supplied in vials containing sterile having activity of 2000 I.U. / 5000 I.U. / 10000 I.U.
Manufactured in India by :
BHARAT SERUMS AND VACCINES LIMITED
How To Properly Mix HCG:
As you all know, hcg comes in a powder form and needs to be mixed with bacteriostatic water in preparation for injections. In this example, we will use a 5,000 unit vial. Obviously, you need to observe the math and adjust according to how you want your hCG concentrated per CC.
Step 1: Transfer 5 CC's of bacteriostatic water into the vial containing your HCG powder. No more than 3 CC's at once.
Step 2: After each bacteriostatic water transfer, you'll need to draw out just as much air to release pressure.
Step 3: Swirl the mix gently and keep it in the refrigerator.
Once you've completed your mix above, you now have a 5,000 iu vial that contains 1,000 iu's of HCG for every CC. So if you want to shoot 250iu, that would be 0.25 CC/ML. Or 25 units on a slim pin. I usually suggest injectable B12 to mix HCG. Which will Help you to get both B12 and HCG in one shot.
How to dose and to the math when mixing the HCG:
A lot of people still don't understand how to calculate their doses after mixing. Note that CC and ML are the same thing. So here is the math to prevent anymore questions about this...
A standard insulin syringe can hold 1 CC in volume. Each barrel will have markings in 1 unit increments up to 100. So each CC displays 100 unit markings.
Step 1: Amount of HCG per CC (result of step 1) DIVIDED BY 100 (number of units on a pin) = amount of hCG per unit.
Example: 10,000 / 10 = 1,000H
Step 2: Amount of hCG per CC (result of step 1) DIVIDED BY 100 (number of units on a pin) = amount of HCG per unit.
Example: 1,000 / 100 = 10
Step 3: Amount desired per injection DIVIDED BY amount of hCG per unit (result of step 2) = Number of units to draw from your mixed vial.
For example: 250 IU / 10 = 25 units. You would draw 25 units, or a quarter of a CC on a pin.
-200x200.jpg "Sifasi 10000IU by Indian Pharmacy")